Loading
A phase 2 trial of Propranolol, Paclitaxel / nab-paclitaxel and Carboplatin in Ovarian cancer, run by Bai-Rong Xia, now recruiting.
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer is a phase 2 interventional study registered as NCT07125391 by Bai-Rong Xia, with 136 participants planned, started 2025-06-20 and due to reach its primary completion in 2026-08-30. Interventions recorded: Propranolol Hydrochloride, Paclitaxel liposome, Carboplatin. Conditions recorded: Ovarian Cancer.
Linked to the drug Propranolol because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Propranolol (Hemangeol) and the tag pipeline.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Carboplatin and the tag pipeline.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Carboplatin and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/